• HyperTrap Heparin HP Column: Precision Purification for Stem

  2026-05-29

  The HyperTrap Heparin HP Column delivers unmatched selectivity and resolution for isolating key signaling mediators from complex biological samples. Its advanced HyperChrom Heparin HP Agarose matrix enables researchers to dissect cancer stem cell pathways, such as CCR7–Notch1 crosstalk, with reproducibility and workflow efficiency that outpaces conventional affinity columns.

• ARCA EGFP mRNA (5-moUTP): Advancing Polyadenylated mRNA Assa

  2026-05-29

  ARCA EGFP mRNA (5-moUTP) sets a new benchmark for polyadenylated mRNA reporter assays by combining high translational efficiency with robust immune evasion. Its advanced capping and 5-moUTP modification streamline fluorescence-based transfection control, enabling reproducible, low-noise detection in mammalian systems.

• PXR Activation by Pregnenolone-16α-carbonitrile Inhibits Hep

  2026-05-28

  This study demonstrates that activation of the pregnane X receptor (PXR) by pregnenolone-16α-carbonitrile (PCN) significantly protects against cholestatic liver injury by inhibiting both canonical and non-canonical pyroptosis in hepatocytes. The findings introduce a mechanistic framework for targeting PXR in hepatic detoxification and highlight new therapeutic avenues against cholestatic pathology.

• Monomethyl Auristatin E (MMAE): Shaping Tumor Plasticity in

  2026-05-28

  Explore how Monomethyl auristatin E (MMAE) uniquely empowers targeted cancer therapy by modulating tumor cell plasticity, with insights into its mechanism, protocol parameters, and translational potential. This in-depth article reveals new perspectives for antibody-drug conjugate payload selection.

• Targeting Tau Ser356 Phosphorylation in Alzheimer's: NUAK In

  2026-05-27

  Taylor et al. (2023) reveal that phosphorylation of tau at serine 356 is closely linked to Alzheimer’s disease progression and can be selectively reduced in human and mouse brain tissue using NUAK kinase inhibition. Their ex vivo experiments highlight both the pathological prominence of p-tau Ser356 and the differential response of mouse versus human tissue to targeted kinase inhibition, informing future therapeutic strategies.

• Merimepodib (VX-497): Selective Oral IMPDH Inhibitor in Rese

  2026-05-27

  Merimepodib (VX-497) is a selective, orally bioavailable inhibitor of inosine monophosphate dehydrogenase (IMPDH), disrupting guanine nucleotide biosynthesis and cellular proliferation. It demonstrates potent antiviral, immunosuppressive, and anticancer activity in vitro and in vivo. This article compiles atomic, evidence-backed claims and protocol guidance for research use.

• Multi-Omics Uncovers ARID1A-Driven Resistance in Melanoma

  2026-05-26

  This study integrates multi-omics to map drug response and resistance networks in BRAF-mutant melanoma, identifying ARID1A loss as a key driver of resistance to BRAF/MAPK inhibitors. The findings reveal actionable resistance nodes and signaling rewiring, offering new targets for improving the durability of melanoma therapies.

• PEDV Relies on Host IMPDH Activity: Insights from Metabolomi

  2026-05-26

  This study reveals that porcine epidemic diarrhea virus (PEDV) manipulates host nucleotide metabolism, specifically targeting IMPDH-dependent guanine biosynthesis to promote replication. The findings highlight IMPDH as a host-directed vulnerability, with both genetic and pharmacological inhibition—using Merimepodib (VX-497)—significantly suppressing viral replication.

• Heparin Sodium in Translational Research: Mechanisms & Innov

  2026-05-25

  This thought-leadership article provides translational researchers with an advanced perspective on the mechanistic action, experimental utility, and strategic frontiers of heparin sodium as a glycosaminoglycan anticoagulant. By bridging foundational anti-coagulant research with nanoparticle delivery systems and emerging insights from plant-derived nanovesicle studies, the article offers actionable protocol guidance, reviews the evolving competitive landscape, and projects the future of blood coagulation pathway research. The piece draws on recent peer-reviewed studies, expert protocols, and APExBIO product data to support decision-making in thrombosis modeling, anti-factor Xa activity assays, and activated partial thromboplastin time (aPTT) workflows.

• 2X Taq PCR Master Mix: Precision PCR for Genotyping & Clonin

  2026-05-25

  Unlock streamlined PCR workflows with the 2X Taq PCR Master Mix (with dye), designed for rapid DNA amplification and direct gel analysis. This ready-to-use master mix accelerates genotyping, TA cloning, and sequence validation—empowering translational research and troubleshooting at the bench.

• Plant Exosome-Like Nanovesicles Mitigate Sertoli Cell Injury

  2026-05-24

  This study demonstrates that exosome-like nanovesicles from Cistanche deserticola (CDELNs) alleviate cyclophosphamide-induced testicular injury by targeting cell cycle arrest in Sertoli cells. The findings reveal a novel miRNA-mediated mechanism with translational promise for male reproductive protection.

• HyperTrap Heparin HP Column: Redefining Affinity Purificatio

  2026-05-23

  Discover how the HyperTrap Heparin HP Column advances high-resolution affinity purification for complex biomolecules—including coagulation factors and nucleic acid enzymes. This deep dive explores its unique technical innovations and their impact on translational cancer research.

• PTEN mRNA Reinstatement: Mechanistic and Strategic Innovatio

  2026-05-22

  Explore the transformative role of EZ Cap™ Human PTEN mRNA (ψUTP) in overcoming PI3K/Akt-driven cancer resistance, with an emphasis on mechanistic rationale, translational research strategy, and the advancing frontier of mRNA-based tumor suppressor restoration. Drawing on recent nanoparticle-mediated delivery breakthroughs and practical protocol guidance, this article delivers actionable insights for researchers seeking robust, durable, and immunologically silent PTEN expression in cancer models.

• Dynamic LRIG1 Expression in Salivary Gland Development Revea

  2026-05-22

  This study employs single-cell RNA sequencing and advanced histology to map the spatial and temporal expression of LRIG1 during murine salivary gland development. The findings clarify LRIG1's critical role in progenitor cell regulation and epithelial maturation, providing a molecular foundation for future research in glandular biology and tissue regeneration.

• Merimepodib (VX-497): Selective IMPDH Inhibitor for Antivira

  2026-05-21

  Merimepodib (VX-497) is a selective, noncompetitive, orally bioavailable inhibitor of inosine monophosphate dehydrogenase (IMPDH) with verified antiviral and immunosuppressive properties. Its mechanism blocks guanine nucleotide biosynthesis, impairing cell proliferation and viral replication. Recent studies confirm its effectiveness against diverse viruses and its role as a research tool in cancer and immunology.

16641 records 1/1110 page Next 12345 下5页 Last page